28414203|t|Self - assembled nanocomplex between polymerized phenylboronic acid and doxorubicin for efficient tumor - targeted chemotherapy
28414203|a|Since the discovery that nano-scaled particulates can easily be incorporated into tumors via the enhanced permeability and retention (EPR) effect, such nanostructures have been exploited as therapeutic small molecule delivery systems. However, the convoluted synthetic process of conventional nanostructures has impeded their feasibility and reproducibility in clinical applications. Herein, we report an easily prepared formulation of self - assembled nanostructures for systemic delivery of the anti-cancer drug doxorubicin (DOX). Phenylboronic acid (PBA) was grafted onto the polymeric backbone of poly(maleic anhydride). pPBA-DOX nanocomplexes were prepared by simple mixing, on the basis of the strong interaction between the 1,3-diol of DOX and the PBA moiety on pPBA. Three nanocomplexes (1, 2, 4) were designed on the basis of [PBA]:[DOX] molar ratios of 1:1, 2:1, and 4:1, respectively, to investigate the function of the residual PBA moiety as a targeting ligand. An acid-labile drug release profile was observed, owing to the intrinsic properties of the phenylboronic ester. Moreover, the tumor - targeting ability of the nanocomplexes was demonstrated, both in vitro by confocal microscopy and in vivo by fluorescence imaging, to be driven by an inherent property of the residual PBA. Ligand competition assays with free PBA pre-treatment demonstrated the targeting effect of the residual PBA from the nanocomplexes 2 and 4. Finally, the nanocomplexes 2 and 4, compared with the free DOX, exhibited significantly greater anti-cancer effects in vitro and even in vivo. Our pPBA-DOX nanocomplex enables a new paradigm for self - assembled nanostructures with potential biomedical applications.
28414203	0	4	Self	T078	C0036588
28414203	7	16	assembled	T052	C1706853
28414203	17	28	nanocomplex	T121	C1254351
28414203	37	48	polymerized	T067	C0314672
28414203	49	67	phenylboronic acid	T109,T130	C0053163
28414203	72	83	doxorubicin	T109,T195	C0013089
28414203	88	97	efficient	T080	C0442799
28414203	98	103	tumor	T191	C0027651
28414203	106	114	targeted	T169	C1521840
28414203	115	127	chemotherapy	T061	C3665472
28414203	138	147	discovery	T052	C1880355
28414203	153	177	nano-scaled particulates	T073	C1450053
28414203	210	216	tumors	T191	C0027651
28414203	225	273	enhanced permeability and retention (EPR) effect	T080	C1280500
28414203	280	294	nanostructures	T073	C1450053
28414203	318	329	therapeutic	T169	C0302350
28414203	345	361	delivery systems	T074	C0085104
28414203	376	386	convoluted	T080	C0205401
28414203	387	404	synthetic process	T052	C1883254
28414203	408	420	conventional	T080	C0439858
28414203	421	435	nanostructures	T073	C1450053
28414203	454	465	feasibility	T062,T170	C0015730
28414203	470	485	reproducibility	T080	C1514863
28414203	489	510	clinical applications	T058	C1880106
28414203	523	529	report	T058	C0700287
28414203	549	560	formulation	T062	C0524527
28414203	564	568	self	T078	C0036588
28414203	571	580	assembled	T052	C1706853
28414203	581	595	nanostructures	T073	C1450053
28414203	600	617	systemic delivery	T074	C0085104
28414203	625	641	anti-cancer drug	T109,T121	C0003392
28414203	642	653	doxorubicin	T109,T195	C0013089
28414203	655	658	DOX	T109,T195	C0013089
28414203	661	679	Phenylboronic acid	T109,T130	C0053163
28414203	681	684	PBA	T109,T130	C0053163
28414203	690	697	grafted	T080	C1527362
28414203	707	725	polymeric backbone	T104,T122	C0032521
28414203	729	751	poly(maleic anhydride)	T121	C1254351
28414203	753	775	pPBA-DOX nanocomplexes	T121	C1254351
28414203	793	799	simple	T080	C0205352
28414203	800	806	mixing	T169	C0205430
28414203	828	834	strong	T080	C0442821
28414203	835	846	interaction	T169	C1704675
28414203	871	874	DOX	T109,T195	C0013089
28414203	883	893	PBA moiety	T109,T130	C0053163
28414203	897	901	pPBA	T104,T122	C0032521
28414203	909	922	nanocomplexes	T121	C1254351
28414203	964	967	PBA	T109,T130	C0053163
28414203	970	973	DOX	T109,T195	C0013089
28414203	975	987	molar ratios	T081	C2825550
28414203	1027	1038	investigate	T169	C1292732
28414203	1043	1051	function	T169	C0542341
28414203	1059	1067	residual	T080	C1609982
28414203	1068	1078	PBA moiety	T109,T130	C0053163
28414203	1084	1093	targeting	T169	C1521840
28414203	1094	1100	ligand	T121	C1254351
28414203	1117	1129	drug release	T070	C3850077
28414203	1142	1150	observed	T169	C1441672
28414203	1165	1185	intrinsic properties	T169	C0439674
28414203	1193	1212	phenylboronic ester	T121	C1254351
28414203	1228	1233	tumor	T191	C0027651
28414203	1236	1245	targeting	T169	C1521840
28414203	1261	1274	nanocomplexes	T121	C1254351
28414203	1298	1306	in vitro	T080	C1533691
28414203	1310	1329	confocal microscopy	T059	C0242842
28414203	1334	1341	in vivo	T082	C1515655
28414203	1345	1365	fluorescence imaging	T060	C0430876
28414203	1386	1403	inherent property	T067	C1562679
28414203	1411	1419	residual	T080	C1609982
28414203	1420	1423	PBA	T109,T130	C0053163
28414203	1425	1450	Ligand competition assays	T059	C0005507
28414203	1461	1464	PBA	T109,T130	C0053163
28414203	1465	1478	pre-treatment	T079	C2709094
28414203	1496	1505	targeting	T169	C1521840
28414203	1506	1512	effect	T080	C1280500
28414203	1520	1528	residual	T080	C1609982
28414203	1529	1532	PBA	T109,T130	C0053163
28414203	1542	1555	nanocomplexes	T121	C1254351
28414203	1578	1591	nanocomplexes	T121	C1254351
28414203	1601	1609	compared	T052	C1707455
28414203	1619	1627	free DOX	T109,T195	C0013089
28414203	1653	1660	greater	T081	C1704243
28414203	1661	1672	anti-cancer	T109,T121	C0003392
28414203	1673	1680	effects	T080	C1280500
28414203	1681	1689	in vitro	T080	C1533691
28414203	1699	1706	in vivo	T082	C1515655
28414203	1712	1732	pPBA-DOX nanocomplex	T121	C1254351
28414203	1747	1755	paradigm	T062	C0681797
28414203	1760	1764	self	T078	C0036588
28414203	1767	1776	assembled	T052	C1706853
28414203	1777	1791	nanostructures	T073	C1450053
28414203	1797	1806	potential	T080	C3245505
28414203	1807	1830	biomedical applications	T058	C0752188